Pharma scrambling to expand gout treatment market

Joint pain caused by gout may be on its way out, as the ever-expanding market encourages the discovery of groundbreaking new therapies, according to a new report by healthcare experts GlobalData.

As the new report explains, pharmaceutical companies are scrambling to expand into the gout market, as it is now the most common form of inflammatory joint disease in men and women aged over 40 years, caused by genetic metabolic defects, kidney impairment, alcohol abuse and even meat-heavy diets. Prevalence has been rising steadily over the last 20 years, due to the increased longevity of the population, alongside dietary changes and increases in obesity.

While the current gout therapeutics market is competitive, due to the availability of a number of treatments, there is a significant unmet need in due to safety concerns and treatment failures.